OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share our experience with mRNA drug development and their anti-tumor efficacy. OncoWuXi Introduction to Nucleic Acid Drugs RNA-based therapies …Read More >

Unlike conventional protein-targeted therapies, nucleic acid therapeutics have the potential for long-lasting effects and greater target specificity. WuXi AppTec provides a comprehensive platform to support the discovery of mRNA drugs.  Our services include mRNA design and production, assessment of mRNA delivery systems, in vitro evaluation, and determination of in vivo efficacy and biodistribution. At AACR …Read More >

RNA interference using small interfering RNA (siRNA) molecules has emerged as a promising therapeutic modality.  To accelerate the discovery of novel siRNAs, WuXi AppTec has established an integrated platform encompassing siRNA sequence design, chemical synthesis/modification, delivery ligand exploration, and activity/off-target assessment. At the TIDES USA 2024 Conference, our scientists presented a poster showcasing the effectiveness …Read More >

Choose excellence, choose WuXi Biology- your reliable partner in oligonucleotide drug discovery. WuXi Biology provides an integrated service platform for support of the discovery of oligonucleotide drugs. Our services cover sequence and modification design of oligonucleotides, in vitro and in vivo biological and PK/PD evaluations, and assessment of oligonucleotide off-target effects. Our broad and deep …Read More >

Design and production of mRNA Design and optimization of mRNA sequences Utilizing the design and optimization techniques for mRNA sequences, UTR screening, and codon optimization Plasmid and DNA template productions for in vitro transcription Employment of a classical three-step purification method Implementation of mono-enzyme digestion and purification through chromatography Research scale mRNA production and characterization …Read More >

Protein kinase N3 (PKN3) is a serine/threonine kinase implicated in tumor progression across multiple cancer types.  PKN3 mRNA is almost undetectable in normal adult tissues but is upregulated in various cancer cells, indicating that siRNA may be a promising approach to inhibit tumor growth by reducing the expression of PKN3.  WuXi AppTec scientists established different siPKN3 molecules and evaluated …Read More >

Despite the success of delivery technologies such as lipid nanoparticles and trivalent GalNAc conjugation, targeted delivery of oligonucleotides to extra hepatic tissues remains a challenge.  WuXi AppTec presented a poster showing the utilization of our peptide-based DNA-encoded library screening platform to identify endocytosis receptor-binding peptides.  The binding affinity of hit peptides was confirmed through biophysical …Read More >

Advances in the understanding of rare disease biology, coupled with innovative technology and therapeutic platforms, has led to progress in the research and development of drugs for rare diseases. Despite these advances, many rare diseases still lack useful treatments and the need for new approaches remains high. In this webinar, we discuss important trends in …Read More >

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held this year in San Diego, CA, USA. As one of the most influential international conferences dedicated to cancer immunotherapy, SITC provides attendees with a cross-disciplinary educational and interactive platform. This meeting focuses on discussing and …Read More >